This is where biosimilars have the greatest potential
A number of biosimilar drugs have already made it onto the European market and the drug class is approaching the US market as well. But where is the greatest potential? And should manufacturers of branded drugs fear biosimilars?
BY BENJAMIN WERNER CHRISTENSEN
In the coming months the US Food and Drug Administration, FDA, is likely to offer approval to the first biosimilar drug ever to be cleared for marketing in the US. But what’s more interesting – from a Danish perspective – is that Novo Nordisk’s main rival Sanofi is about to see biosimilar competition for its top-seller Lantus. The question is how big a chunk of the US market biosimilars will really capture.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
CEO: The door is open for biosimilars and biobetters
For abonnenter
13 copies to compete for Novo's billions
For abonnenter
Pharma flocks to biological copies
For abonnenter
